Arrivent Biopharma Inc (AVBP)

$FHLC $BVS $BCRX $AVBP https://wallstreetwaves.com/peek-under-the-hood-fhlc-has-21-upside/

$AVBP EWTX, IMTX, VRNA, SWTX (went buyout), IRON, MIRM, RYTM, RVMD, MLTX, AVBP, I like FATE too.

$AVBP a tiny little bit above VWAP

Jones Trading updates rating for ArriVent BioPharma ( $AVBP ) to Buy, target set at 40.

HC Wainwright & Co. has updated their rating for ArriVent BioPharma ( $AVBP ) to Buy with a price target of 40.

News out $AVBP Learn to Evaluate (AVBP) using the Charts https://marketwirenews.com/news-releases/learn-to-evaluate-avbp-using-the-charts-8596347924061899.html $AVBP

$AVBP hope to get a positive update on furmonertinib in PACC mutations soon.

$AVBP's latest data on SqueezeFinder

B. Riley Securities has adjusted their stance on ArriVent BioPharma ( $AVBP ), setting the rating to Buy with a target price of 37.

I found you an Oversold RSI (Relative Strength Index) on the daily chart of ArriVent BioPharma, Inc. Common Stock. Is that bullish or bearish? $AVBP #RsiOversold #NASDAQ

Guggenheim has adjusted their stance on ArriVent BioPharma ( $AVBP ), setting the rating to Buy with a target price of 45.

HC Wainwright & Co. updates rating for ArriVent BioPharma ( $AVBP ) to Buy, target set at 39.

$AVBP ArriVent Biopharma reports FY24 EPS ($2.56), consensus ($2.69) "This has been a productive year for ArriVent that included strong achievement across our firmonertinib clinical programs and significant execution of our company strategy through the expansion of our ADC portfolio. The differentiated potential of firmonertinib to address classical and uncommon EGFR mutations was reinforced by the robust anti-tumor activity in NSCLC patients with EGFR PACC mutations reported at the World Conference on Lung Cancer, and the preclinical data presented at AACR" said Bing Yao, CEO. "We also bolstered our ADC portfolio with the recent in-licensing of ARR-217 and research collaboration with Alphamab, underscoring our commitment to further expand our pipeline and develop new innovative therapies to potentially treat cancer patients with unmet medical need. We have achieved our target enrollment of 375 patients in our global, pivotal Phase 3 monotherapy study of firmonertinib in first-line NSCLC patients with EGFR exon 20 insertion mutations. In addition, we plan to provide an update on our plans to investigate firmonertinib as monotherapy in first line NSCLC patients with EGFR PACC mutations in the first half of 2025. For our ADC portfolio, we selected our next-generation ADC candidate, ARR-002, for IND-enabling activities. Our focus continues to be on executing across our near-term catalysts and we are poised for an impactful year ahead."

$AVBP Watch / Opportunity H.C. Wainwright raises target price to $39 from $36

WATCHLIST JAN 22 2025 $AVBP ArriVent BioPharma Entered Exclusive License With Lepu Biopharma For MRG007, An Antibody Drug Conjugate For Treatment Of Gastrointestinal Cancers $INBX Inhibrx Reports Preliminary Efficacy And Safety Data From Phase 1 Trial Of Ozekibart (INBRX-109) For Treatment Of Colorectal Cancer; Initiates New Expansion Cohort To Validate Findings $CRSP Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases $NTRA Reported Earlier, Natera To Reveal New Insights On Signatera's Clinical Utility And Innovations In Tissue-Free MRD At ASCO GI 2025 $EXAS Exact Sciences Says Oncodetect Test Achieved Primary Endpoint In Second Clinical Validation Study, Extending Prognostic Value Into Stages II And IV Colon Cancer And Rectal Cancer

$BVAXF Tweet says: This Feb 5th #BIOV #BVAXF has been invited to present on its #DPX platform for infectious disease applications to #CEPI (the Coalition for Epidemic Preparedness Innovations)---founded by the governments of Norway and India, the Bill & Melinda Gates Foundation, Wellcome Foundation, and the World Economic Forum to accelerate the development of vaccines other countermeasures against epidemic & pandemic threats This is going to to be amazing exposure for BIOV $PRAX $BLTE $IMCR $AVBP

$AVBP why doesn't the guy (who went and created 3 different accounts) ever tag $MYNZ when talking it up on this board.

$AVBP My solids RYTM, EWTX, AVBP, IMTX, SWTX, IRON, MIRM, DAWN

$AVBP loaded more today.